Department of Pharmaceutical Chemistry and Center for New Drugs Discovery and Development (C3D), Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hoan Kiem District, Hanoi, Vietnam
*Corresponding Author E-mail: nhnam@hotmail.com
Online published on 13 March, 2013.
An improved synthesis of 3-oxo-4-aza-5α-androst-1-ene-17β-(N-tert-butylcarboxamide), commonly known as finasteride (1), a drug widely used for the treatment of benign prostatic hyperplasia (BPH), has been implemented via seven steps in an overall yield of 20.01% starting from 4-androsten-3,17-dione (AD). Conditions of several steps have been improved to be less expensive and more commercially viable compared to reported synthesis in literature.
Finasteride, benign prostatic hyperplasia, androst-4-en-3,17-dione, synthesis
